Breast Cancer Trials / Trials in Michigan
120 Recruiting Trials

Clinical Trials
for Breast Cancer in Michigan

120 clinical trials for Breast Cancer are currently recruiting participants at study sites in Michigan. Study-related care is provided at no cost.

120
Recruiting trials
241
Study sites
66
Cities
80
Industry-sponsored
39
Phase 2
33
Phase 3

Breast Cancer clinical trials in Michigan: what to expect

Breast cancer trials are sorted first by subtype, because the treatments differ: hormone-receptor-positive, HER2-positive (including the newer HER2-low group) and triple-negative disease each have their own studies. Most recruiting trials test a new drug or combination, including targeted pills, antibody-drug conjugates and immunotherapy, either for metastatic cancer or before and after surgery for early-stage disease. Others study less surgery or radiation, ways to reduce recurrence, and screening for people at higher risk.

In Michigan, recruiting breast cancer studies are concentrated in Detroit, Grand Rapids, Ann Arbor and Lansing, with sites in 62 other cities. 80 of the 120 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who breast cancer trials usually look for

Listings name the subtype, the stage (early or metastatic) and how many treatments you may already have had. Early-stage trials often enroll between diagnosis and surgery, or in the months after surgery; metastatic trials usually enroll when a treatment has stopped working. Some specify menopausal status or a particular mutation (BRCA, PIK3CA, ESR1), which the site can test for. Nearly all require that you are well enough for daily activity and that recent blood work is adequate.

Your receptor status is on your pathology report; the site will confirm it from that report, so you do not need to know it by heart to ask.

What taking part involves

Screening reviews your pathology and scans and adds blood work, sometimes a biopsy. Treatment then runs in cycles, with infusions every two to three weeks or daily pills, and scans every two to three months to check the response. Early-stage trials follow you for years after treatment ends, usually with a visit or call every few months. Study drugs and study-specific tests are free; care you would receive anyway is billed to insurance as usual. Placebo, when used, is added to standard treatment.

Questions worth asking the study team

How the study treatment compares with what your oncologist would otherwise recommend; whether the trial is randomized and what the other arm receives; what happens if the cancer grows or returns; and how visits fit around work and family. Many trials now allow some visits at a local clinic.

Showing 20 of 120 recruiting Breast Cancer trials in Michigan

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3 Jonesboro, Arkansas +4 sites NCT06757634
This trial is looking for adults with advanced breast cancer that is HR-positive and HER2-negative. Participants will receive treatment involving gedatolisib along with other medications.
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
PHASE3 Goodyear, Arizona +4 sites NCT06790693
This trial is looking for adults with a specific type of advanced breast cancer to test a new treatment combo. Participants will receive either the new treatment or a placebo along with standard care.
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
PHASE3 Greenbrae, California +4 sites NCT05646862
This trial is looking for people with advanced breast cancer that has specific mutations and has not improved after certain treatments. Participants will compare two treatment combinations to see which is more effective and safe.
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3 Daphne, Alabama +4 sites NCT06103864
This trial is looking for patients with a specific type of breast cancer that is not treatable by surgery. Participants will receive a treatment called Dato-DXd, with or without another drug, or a standard chemotherapy treatment.
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3 Hot Springs, Arkansas +4 sites NCT07085767
This trial is looking for adults with advanced breast cancer that hasn’t been treated before. Participants will receive palazestrant with ribociclib or letrozole with ribociclib to see which treatment works better.
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3 Daphne, Alabama +4 sites NCT06492616
This trial is looking for women and men with early breast cancer that has a high risk of coming back. Participants will compare the effects of elacestrant with standard treatment after being on another therapy for a while.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3 Phoenix, Arizona +4 sites NCT06748222
This trial is looking for younger women who have survived breast cancer and are experiencing depression. Participants will try two different mindfulness programs, one led by an instructor via Zoom and the other through a mobile app.
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
PHASE2 Long Beach, California +4 sites NCT07102381
This trial is looking for people with early-stage HER2-positive breast cancer to see if zanidatamab combined with chemotherapy is safe and effective. Participants will need to undergo surgery after the treatment.
Recruiting
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
PHASE2 Flint, Michigan +4 sites NCT01766297
This trial is looking for women over 50 with early stage breast cancer. Participants will receive proton radiation therapy to see its effects on their cancer.
Recruiting
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
PHASE1 Ann Arbor, Michigan +2 sites NCT05996107
This trial is looking for women with high-risk breast cancer who have had surgery and completed chemotherapy. Participants will take Ribociclib while receiving radiation therapy for a short period.
Recruiting
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NA Birmingham, Alabama +4 sites NCT05625659
Recruiting
Quantitative MRI Assessment of Breast Cancer Therapy Response
N/A Royal Oak, Michigan +3 sites NCT05704062
This trial is looking for patients with breast cancer who will receive chemotherapy before surgery. Participants will undergo MRI scans to help measure how well their treatment is working.
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
PHASE1 Phoenix, Arizona +4 sites NCT06590857
Recruiting
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
PHASE3 Sterling Heights, Michigan +4 sites NCT07541079
This trial is looking for women with early breast cancer who have had problems with a previous hormonal treatment. If you join, you will switch to taking giredestrant as part of your cancer care.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
PHASE1 Hot Springs, Arkansas +4 sites NCT07310420
This trial is looking for premenopausal women aged 18 to 55 who have been diagnosed with early or advanced hormone receptor positive breast cancer. Participants will receive ZOLADEX to help assess ovarian suppression.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Birmingham, Alabama +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
PHASE3 Gilbert, Arizona +4 sites NCT06380751
This trial is looking for adults with certain types of advanced breast cancer. Participants will take either a combination of drugs or a standard treatment chosen by their doctor to see which works better.
Recruiting
See all 120 Breast Cancer trials in Michigan

Where the Breast Cancer studies are in Michigan

Research sites running the most studies
  • Karmanos Cancer Institute, Detroit17 trials
  • Henry Ford Hospital, Detroit14 trials
  • University of Michigan Rogel Cancer Center, Ann Arbor12 trials
  • Genesys Hurley Cancer Institute, Flint11 trials
  • Munson Medical Center, Traverse City11 trials
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton11 trials
By city

Counts are recruiting studies listing at least one site in Michigan, from ClinicalTrials.gov, refreshed every two days.

Breast Cancer clinical trials in Michigan: common questions

How many Breast Cancer clinical trials are recruiting in Michigan?
TrialFinder currently lists 120 recruiting Breast Cancer clinical trials with study sites in Michigan. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Breast Cancer clinical trials located in Michigan?
Study sites for the Breast Cancer trials listed on this page include Flint, Ann Arbor, Royal Oak, Sterling Heights. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Breast Cancer clinical trial in Michigan?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Breast Cancer trials in Michigan also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Breast Cancer clinical trial in Michigan?
Each study sets its own criteria based on age, Breast Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Do I need to know my receptor status to join a breast cancer trial?
It helps, because trials are organized by subtype, but the study site reads it from your pathology report. If a trial needs a test you have not had, such as HER2-low or a BRCA result, the site arranges it.
Are there trials for early-stage breast cancer?
Yes. Early-stage trials enroll before surgery, after surgery, or during the years of hormone therapy that follow, and test ways to lower the chance the cancer returns. The listing says which window it enrolls in.
Will a trial replace the treatment my oncologist planned?
Sometimes it is the plan, with a new drug added or compared; sometimes it is an alternative to discuss. Bring the trial page to your oncologist, who can refer you to the site or advise on timing.
Breast Cancer Trials in Other States
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Helpful Reading
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Breast Cancer trials near you in Michigan.

Get Matched — Free
No insurance required
About Breast Cancer Trials

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Breast Cancer trials →
Other Conditions in Michigan
Diabetes Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
All trials in Michigan →